Emergent BioSolutions Inc.
EBS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001367644
No open-market purchases or sales by Emergent BioSolutions Inc. insiders were filed in the last 90 days; 194 institutions reported holding it in 13F filings for Q2 2026, worth $373.6M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Emergent BioSolutions Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 233 | 3 | 211 | −19 |
| Shares | 40.8M | 250 | 40.6M | −155.2K (−0.4%) |
| Value | $1.28B | $7.21K | $852.4M | −$425.9M (−33.3%) |
3 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (28)
Institutions that held Emergent BioSolutions Inc. at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (47)
Institutions that held Emergent BioSolutions Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
Not filed for Q3 2022 yet (3)
Institutions that held Emergent BioSolutions Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Private Capital Group, LLC | 171 | $5.00K |
| Exane Derivatives | 39 | $1.21K |
| Fieldpoint Private Securities, LLC | 40 | $1.00K |